ES2170769T3 - Procedimiento de tratamiento de secreciones pulmonares retenidas. - Google Patents

Procedimiento de tratamiento de secreciones pulmonares retenidas.

Info

Publication number
ES2170769T3
ES2170769T3 ES94919422T ES94919422T ES2170769T3 ES 2170769 T3 ES2170769 T3 ES 2170769T3 ES 94919422 T ES94919422 T ES 94919422T ES 94919422 T ES94919422 T ES 94919422T ES 2170769 T3 ES2170769 T3 ES 2170769T3
Authority
ES
Spain
Prior art keywords
lantibiotic
subject
treatment
disclosed
retained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94919422T
Other languages
English (en)
Inventor
Y Vedia Luis M Molina
Monroe Jackson Stutts
Richard C Boucher Jr
David C Henke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Molichem Medicines Inc
University of North Carolina System
Original Assignee
University of North Carolina at Chapel Hill
Molichem Medicines Inc
University of North Carolina System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, Molichem Medicines Inc, University of North Carolina System filed Critical University of North Carolina at Chapel Hill
Application granted granted Critical
Publication of ES2170769T3 publication Critical patent/ES2170769T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

SE PRESENTA UN METODO PARA FACILITAR LA LIMPIEZA DE SECRECIONES PULMONARES RETENIDAS EN UN SUJETO UTILIZANDO LANTIBIOTICOS. EL METODO COMPRENDE LA ADMINISTRACION A LOS PULMONES DEL SUJETO DE UNA CANTIDAD EFECTIVA DE UN LANTIBIOTICO. EL LANTIBIOTICO SE ADMINISTRA PREFERIBLEMENTE MEDIANTE APLICACION TOPICA EN EL EPITELIO RESPIRATORIO, TAL COMO MEDIANTE LA GENERACION DE UN AEROSOL DEL MISMO QUE LUEGO ES INHALADO POR EL SUJETO. UN LANTIBIOTICO PREFERIDO PARA LLEVAR A CABO LA INVENCION ES LA DURAMICINA. EL METODO PUEDE UTILIZARSE EN EL TRATAMIENTO DE ENFERMEDADES TALES COMO LA FIBROSIS CISTICA, LA BRONQUITIS CRONICA Y EL ASMA. TAMBIEN SE PRESENTA UN METODO PARA COMBINAR LA TUBERCULOSIS QUE COMPRENDE LA ADMINISTRACION DE UN LANTIBIOTICO A UN SUJETO QUE NECESITE EL TRATAMIENTO.
ES94919422T 1993-06-09 1994-06-08 Procedimiento de tratamiento de secreciones pulmonares retenidas. Expired - Lifetime ES2170769T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/074,315 US5512269A (en) 1993-06-09 1993-06-09 Method of treating retained pulmonary secretions
PCT/US1994/006486 WO1994028726A2 (en) 1993-06-09 1994-06-08 Method of treating retained pulmonary secretions

Publications (1)

Publication Number Publication Date
ES2170769T3 true ES2170769T3 (es) 2002-08-16

Family

ID=22118924

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94919422T Expired - Lifetime ES2170769T3 (es) 1993-06-09 1994-06-08 Procedimiento de tratamiento de secreciones pulmonares retenidas.

Country Status (11)

Country Link
US (5) US5512269A (es)
EP (2) EP0764028B1 (es)
JP (2) JP4027968B2 (es)
AT (1) ATE212854T1 (es)
AU (1) AU696374B2 (es)
CA (1) CA2164517C (es)
DE (1) DE69429832T2 (es)
DK (1) DK0764028T3 (es)
ES (1) ES2170769T3 (es)
PT (1) PT764028E (es)
WO (1) WO1994028726A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5908611A (en) * 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5866539A (en) * 1995-06-23 1999-02-02 Ambi Inc. Method for the control of antibiotic-resistant gram positive bacteria and treatment of infection
US5910479A (en) * 1996-10-18 1999-06-08 Ambi Inc. Method for the treatment of Streptococcus pneumoniae infection
DE19745583A1 (de) * 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
EP1079807B1 (en) * 1998-05-27 2006-09-13 Euro-Celtique S.A. Use of preparations for the application of antiseptic agents and/or agents promoting the healing of wounds to the lower respiratory tract
US6323191B1 (en) 1998-06-19 2001-11-27 Genzyme Corporation Small molecule chloride transport
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
AU750414B2 (en) * 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
HUP0105226A3 (en) * 1998-12-17 2003-03-28 Pathogenesis Corp Seattle Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) * 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
WO2000075365A2 (en) * 1999-06-08 2000-12-14 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
EP1487407A4 (en) * 2002-03-12 2010-08-25 Microdose Therapeutx Inc SITE SPECIFICITY ADMINISTRATION OF MEDICAMENTS SIMULTANEOUSLY TAKEN BY INHALATION
US7678386B2 (en) 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
NZ537690A (en) 2002-07-15 2009-07-31 Univ Texas Antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections
US7378386B2 (en) 2002-07-15 2008-05-27 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives
US7384909B2 (en) 2002-07-15 2008-06-10 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
US7511124B2 (en) * 2002-07-15 2009-03-31 Board Of Regents, The University Of Texas System Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
US7879801B2 (en) * 2002-07-15 2011-02-01 Board Of Regents, The University Of Texas System Compositions comprising cell-impermeant duramycin derivatives
US7828739B2 (en) * 2002-08-27 2010-11-09 Precision Pulsus, Inc. Apnea detection system
US6869402B2 (en) * 2002-08-27 2005-03-22 Precision Pulsus, Inc. Method and apparatus for measuring pulsus paradoxus
AU2003275129A1 (en) * 2002-10-10 2004-05-04 Molichem Medicines, Inc. Nucleic acids encoding duramycin
EP1560540A4 (en) * 2002-10-18 2008-03-19 Molichem Medicines Inc METHOD FOR TREATING DRY EYES WITH LANTIBIOTICS
DE10261782A1 (de) * 2002-12-19 2004-07-01 Dr. Petry Genmedics Gmbh Neue Gene und Genprodukte
WO2004080427A2 (en) * 2003-03-12 2004-09-23 Schneider Daniel J Method of preventing and treating infections that attack mucosa and assisting rehabilitation thereafter using topically applied ascorbic acid
JP2007524379A (ja) * 2003-03-31 2007-08-30 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン 上皮ナトリウムチャンネル関連障害のＰｈａｒｍｉｃｏ−遺伝子治療
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7479481B2 (en) * 2004-05-06 2009-01-20 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
NZ577196A (en) * 2005-01-20 2011-06-30 Biomarck Pharmaceuticals Ltd Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
BRPI0616642A2 (pt) 2005-09-29 2011-06-28 Nektar Therapeutics formulações de antibióticos, doses unitárias, kits e métodos
US20070243262A1 (en) * 2005-12-21 2007-10-18 Hurley Kevin P Stable S-nitrosothiol formulations
GB0600928D0 (en) * 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
US20070238652A1 (en) * 2006-02-08 2007-10-11 Biosynexus Incorporated Neutralization of bacterial spores
CA2651180A1 (en) * 2006-04-28 2007-11-08 University Of Iowa Research Foundation Methods and compounds to alter virus infection
ZA200900550B (en) * 2006-07-26 2010-03-31 Biomarck Pharmaceuticals Ltd Methods for attenuating release of inflammatory mediators and peptides useful therein
US20080138397A1 (en) * 2006-10-24 2008-06-12 Aradigm Corporation Processes for taste-masking of inhaled formulations
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
WO2009141264A2 (en) * 2008-05-20 2009-11-26 Boehringer Ingelheim Vetmedica Gmbh Gallidermin to treat infections of the respiratory tract
NZ594011A (en) 2009-01-14 2013-12-20 Novacta Biosystems Ltd Deoxyactagardine derivatives
JP5731407B2 (ja) 2009-02-04 2015-06-10 ノヴァクタ バイオシステムズ リミティッド アクタガルジン誘導体
CA2784041C (en) 2010-01-05 2017-11-07 Microdose Therapeutx, Inc. Inhalation device and method
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
BR112015014178A2 (pt) 2012-12-17 2017-07-11 Parion Sciences Inc compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida
PT2931713T (pt) 2012-12-17 2017-02-22 Parion Sciences Inc Derivados de cloro-pirazina carboxamida úteis para o tratamento de doenças favorecidas por insuficiente hidratação das mucosas
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
AU2017229347A1 (en) 2016-03-07 2018-11-01 University Of Iowa Research Foundation AAV-mediated expression using a synthetic promoter and enhancer
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683072A (en) * 1968-03-14 1972-08-08 William J Miller A methobottromycin and process for treating poultry infections
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
JPS6234923A (ja) * 1985-08-09 1987-02-14 Hitachi Ltd 新規な重合体
ES2032831T5 (es) * 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
AU631803B2 (en) * 1988-06-22 1992-12-10 Applied Microbiology, Inc Nisin compositions for use as enhanced, broad range bactericides
US5135910A (en) * 1988-06-22 1992-08-04 The Public Health Research Institute Of The City Of New York Nisin compositions for use as enhanced, broad range bactericides
US4980163A (en) * 1989-03-01 1990-12-25 Public Health Research Institute Of The City Of New York Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection
DE3938140A1 (de) * 1989-11-16 1991-08-08 Beiersdorf Ag Desodorierende kosmetische mittel
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5162348A (en) * 1990-05-24 1992-11-10 Imperial Chemical Industries Plc Treatment of cystic fibrosis
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
JPH05500229A (ja) * 1991-04-12 1993-01-21 東レ株式会社 固体ポリペプチド微粒子のエアロゾル製剤とその製造方法
US5559096A (en) * 1991-04-15 1996-09-24 Applied Microbiology, Inc. Pharmaceutical compositions against gastric disorders
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5384128A (en) * 1993-03-02 1995-01-24 University Of Alabama Research Foundation Method of and compounds for treatment for cystic fibrosis

Also Published As

Publication number Publication date
JP4027968B2 (ja) 2007-12-26
US5716931A (en) 1998-02-10
US5849706A (en) 1998-12-15
WO1994028726A3 (en) 1995-03-02
AU7057894A (en) 1995-01-03
DE69429832D1 (de) 2002-03-21
CA2164517A1 (en) 1994-12-22
PT764028E (pt) 2002-06-28
ATE212854T1 (de) 2002-02-15
DK0764028T3 (da) 2002-03-18
US5512269A (en) 1996-04-30
JP2005206612A (ja) 2005-08-04
US5683675A (en) 1997-11-04
JPH09501413A (ja) 1997-02-10
DE69429832T2 (de) 2002-08-14
EP0764028B1 (en) 2002-02-06
CA2164517C (en) 2010-01-19
WO1994028726A2 (en) 1994-12-22
EP0764028A2 (en) 1997-03-26
EP1166794A3 (en) 2003-03-12
AU696374B2 (en) 1998-09-10
EP1166794A2 (en) 2002-01-02
US5651957A (en) 1997-07-29

Similar Documents

Publication Publication Date Title
ES2170769T3 (es) Procedimiento de tratamiento de secreciones pulmonares retenidas.
EP0682526A4 (en) LENGTH ADMINISTRATION OF SCR1 AND OTHER COMPLEMENT INHIBITORS.
EA200100338A1 (ru) Способ и устройство для введения действующего вещества в виде аэрозоли в легкие пациента
EP0754069A4 (en) METHOD OF TREATING PULMONARY VASOCONSTRICTION AND ASTHMA
CA2146954A1 (en) Breath activated nicotine inhalers
GB9425160D0 (en) Medicaments
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
DK0656207T3 (da) Aerosolformuleringer uden chlorfluorcarbonforbindelser
NL300342I1 (nl) Inrichting voor de behandeling van pulmonaire vasoconstrictie en van astma
DE69518334D1 (de) Pharmazeutische aerosol welche mindestens ein zucker enthält
CA2155200A1 (en) Use of topical anesthetics for the treatment of eosinophil-associated diseases
HUP9902675A2 (hu) Fluorozott-szénhidrogén-hajtógázt tartalmazó mometazon-furoát aeroszol
GR3022083T3 (en) Inhalant based on taurine
CZ220396A3 (en) Process of treating a medicament to aerosol, the use of a gas mixture and a therapeutical preparation
van der Schans Physiotherapy and bronchial mucus transport
WO1992011025A3 (en) Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases
RU96110101A (ru) Способ повышения работоспособности и снижения утомляемости
RU2001125081A (ru) Способ лечения бронхиальной астмы

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 764028

Country of ref document: ES